Circulating MMP-3 levels were also reduced by TNF-α-blocker treatment in ankylosing spondylitis, and there was a correlation between changes in MMP-3 and changes in disease activity during treatment (Maksymowych et al. 2008). Here, MMP3 is linked to ankylosing spondylitis.